株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

メチシリン耐性黄色ブドウ球菌(MRSA)感染症:パイプライン製品の分析

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 219820
出版日 ページ情報 英文 374 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.28円で換算しております。
Back to Top
メチシリン耐性黄色ブドウ球菌(MRSA)感染症:パイプライン製品の分析 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 374 Pages
概要

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症は、通常のブドウ球菌感染症の治療に広く用いられる抗生物質に耐性を持つようになる、ブドウ球菌の株によって引き起こされます。素因には、血液透析、免疫系の弱化、入院、創傷などがあります。症状には、湿疹、疲労、胸痛、発熱および腫れが含まれます。MRSAは抗生物質の利用および衛生状況の維持によって管理できます。

当レポートでは、メチシリン耐性黄色ブドウ球菌(MRSA)感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースなどについて、体系的な情報を提供しています。

イントロダクション

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症の概要

治療薬の開発

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症:治療薬の評価

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症の治療薬開発に従事している企業

薬剤プロファイル

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症:休止中のプロジェクト

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症:開発が中止された製品

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症:製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9337IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 14, 10, 70, 31 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 22 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AstraZeneca Plc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3J Therapeutics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellceutix Corp, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cempra Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Common Pharma Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corp, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CytaCoat AB, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dermala Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lipocure Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novalex Therapeutics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ovensa Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Prommune Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top